Sun Pharma signs agreement with US government to prioritise access to affordable medicines

image credit- freepik

Mumbai-based Sun Pharmaceutical Industries joined several pharmaceutical companies at a White House ceremony to announce agreements with the US government aimed at prioritising access to affordable medicines for millions of American patients.

As part of its agreement, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programmes. Sun Pharma also commits to MFN pricing for future innovative medicine launches. The agreement recognises Sun Pharma’s investment in the US market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years.

Sun Pharma initially built its US presence on a foundation of high-quality generics followed by an increasing emphasis on innovative and specialty medicines. The company ranks second by prescriptions in US dermatology and continues to expand across dermatology and immunology, cutaneous oncology, and ophthalmology, complementing a robust consumer health products and generics business. The US is Sun Pharma’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.

Commitment to the US market was further underscored earlier this year through Sun Pharma’s definitive agreement to acquire Organon & Co. at an enterprise value of $11.75 billion - a milestone that reflects Sun Pharma's continued investment in American patients, healthcare providers, and communities.